SHELTON, CT / ACCESS Newswire / July 30, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), and a clinical stage, leading global pioneer in the development of ...

But this time, the unknown is hitting the industry in a different way from when Prasad was tapped to lead CBER less than ...

Key Points Penumbra topped analyst forecasts with $339.5 million in GAAP revenue and $0.86 non-GAAP EPS, driven by double-digit U.S. thrombectomy growth. Gross margin (GAAP) expanded sharply to 66.0%, ...

FDA Commissioner Marty Makary said the FDA’s review process will not slow down despite layoffs at the Department of Health ...

The gene therapy chief wanted to block fast-track drug approvals.

Dr. Vinay Prasad is stepping down as the Food and Drug Administration’s top vaccine regulator after a brief tenure.

Under the Inflation Reduction Act, medications with the same active ingredient will be treated as the same drug for price ...

Shares of drugmaker Sarepta Therapeutics surged in afterhours trading Monday after the company said it would resume shipping its gene therapy.

Arquitos Capital Management gained 13.1% in Q2 2025. Learn how they turned market uncertainty into opportunity with Liquidia ...

It's shaping up to be a big year for Boehringer Ingelheim—at least if the FDA plays ball. | Boehringer Chief Medical Officer Lykke Hinsch Gylvin, M.D., set out the German drugmaker's plans to launch ...

The Trump administration is inching closer to banning fluoride tablets and drops often prescribed to kids who don’t have ...

The FDA has decided not to approve glofitamab plus gemcitabine and oxaliplatin to treat certain patients with relapsed/refractory DLBCL.